Solvay/€SOLB
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Solvay
Solvay SA, listed under ticker SOLB, is a Belgium-based international chemical and advanced materials company. It operates through several business segments including Advanced Materials, Advanced Formulations, Performance Chemicals, and Corporate & Business Services. The company was founded in 1863 and has established itself as a key player in producing a wide range of products used in applications such as automotive, electronics, and healthcare.
- Ticker
- €SOLB
- Sector
- Materials
- Primary listing
- BSE
- Employees
- 8,400
- Headquarters
- Brussels, Belgium
- Website
- www.solvay.com
Solvay Metrics
BasicAdvanced
€2.6B
842.73
€0.03
0.25
€1.70
6.90%
Price and volume
Market cap
€2.6B
Beta
0.25
52-week high
€29.82
52-week low
€23.60
Average daily volume
334K
Dividend rate
€1.70
Financial strength
Current ratio
1.15
Quick ratio
0.816
Long term debt to equity
1.637
Total debt to equity
2.013
Dividend payout ratio (TTM)
6,350.00%
Interest coverage (TTM)
3.72%
Profitability
EBITDA (TTM)
587
Gross margin (TTM)
21.38%
Net profit margin (TTM)
0.09%
Operating margin (TTM)
7.98%
Effective tax rate (TTM)
92.37%
Revenue per employee (TTM)
€540,000
Management effectiveness
Return on assets (TTM)
3.69%
Return on equity (TTM)
0.78%
Valuation
Price to earnings (TTM)
842.727
Price to revenue (TTM)
0.564
Price to book
2.46
Price to tangible book (TTM)
35.27
Price to free cash flow (TTM)
6.399
Free cash flow yield (TTM)
15.63%
Free cash flow per share (TTM)
3.855
Dividend yield (TTM)
6.90%
Growth
Revenue change (TTM)
-7.67%
Earnings per share change (TTM)
-97.76%
3-year revenue growth (CAGR)
8.90%
10-year revenue growth (CAGR)
-7.06%
3-year earnings per share growth (CAGR)
-86.74%
10-year earnings per share growth (CAGR)
-38.22%
3-year dividend per share growth (CAGR)
-29.29%
10-year dividend per share growth (CAGR)
-7.83%
What the Analysts think about Solvay
Analyst ratings (Buy, Hold, Sell) for Solvay stock.
Analyst projections of the future price of Solvay stock.
Bulls say / Bears say
Solvay kept its 2026 EBITDA guidance at €770–850 million and expects at least €200 million of free cash flow, with around €300 million of cumulative structural savings. Delivery depends partly on restarting its Saudi peroxide plant in the third quarter, but the targets offer a defined recovery path. (Solvay)
Solvay plans to more than double Taiwan output of high-purity hydrogen peroxide by year-end to serve semiconductor makers. It also aims to at least triple the electronics-peroxide business over five to seven years, giving it exposure to chip-industry growth. (Reuters)
Solvay is expanding rare-earth separation at La Rochelle after securing customer commitments, and plans industrial-scale dysprosium and terbium production from autumn 2026. The investment could give it a larger role in European supply chains for magnets and other advanced applications. (Solvay)
Soda ash is facing a difficult supply-demand balance: Solvay says global overcapacity tipped the market in 2025, with demand growth forecast at only about 0.5% in 2026 while capacity continues to rise. That pressure is already weighing on export-market prices. (Solvay)
First-half free cash flow was only €15 million, while net debt reached €1.8 billion and leverage stood at 2.3 times at June-end. Solvay’s €200 million full-year cash-flow target therefore requires a much stronger second half, leaving execution risk if operations or working capital disappoint. (Investegate, Solvay)
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2026.
Solvay Financial Performance
Revenues and expenses
Solvay Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Solvay
AllEURGBPUSD
Fund name | Fund size | €SOLB weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.14% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.14% |
iShares MSCI World Small Cap$WSML | $9B | 0.02% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.02% |
iShares MSCI World Small Cap£WLDS | £6.7B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.